Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update
Date:2/23/2012

initiated a phase I clinical study of IDX719, its NS5A inhibitor candidate. The first part of the study is evaluating the safety, pharmacokinetics and food effect of IDX719 in 48 healthy volunteers at single doses ranging from 5 to 100 mg. Dosing up to 50 mg has been completed in healthy volunteers and to date IDX719 has been well tolerated. A cohort of eight HCV genotype 1-infected patients received single doses of IDX719 of either 1, 5, 10 or 25 mg (2 patients per dose). Mean maximal viral load reductions were 1.9 log(10), 2.6 log(10), 3.3 log(10) and 3.7 log(10), respectively. A 3-day proof-of-concept segment of the study in treatment-naive genotype 1 HCV-infected patients is expected to begin in the second quarter of 2012 with additional cohorts of genotype 2, 3, or 4 HCV-infected patients to be added during the study.

Nucleotide Discovery ProgramIn January 2012, Idenix selected two nucleotide inhibitors, IDX19368 and IDX19370, as potential clinical candidates from its novel nucleotide prodrug discovery program. IDX19368 has demonstrated strong potency in preclinical studies and as a result the Company has chosen IDX19368 as its lead candidate and expects to submit an investigational new drug application (IND) for IDX19368 in mid-2012. The Company continues to identify new promising compounds and evaluate multiple candidates for further development from this discovery program.

"Our focus for 2012 will be to build on the progress we made last year through the continued advancement of our pipeline of novel HCV drug candidates," said Ron Renaud, Idenix's President and Chief Executive Officer. "Now that the partial clinical hold has been removed for IDX184, we will be able to explore the full potential of this promising nucleotide polymerase inhibitor in combination with other DAAs in a broad phase IIb program. The early results are promising for IDX719, our NS5A inhibitor, in HCV patients and we look forward to completing the phase I clinical tria
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Wash. , Dec. 19, 2014  Advanced ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that a Life ... has been awarded for which AMIC is the ... State University (WSU) for the proposal titled "Optimized ...
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... marketplace, innovative consumer research and marketing communication tools ... rich and globally competitive – consequently consumers, desires, ... In this environment, market research groups across ... research and marketing communication tools. However, the adoption ...
(Date:12/19/2014)... Dec. 18, 2014 Somewhere between dropping five ... was forgotten. But Audicus , a next-generation hearing ... this new year. Hearing loss is the ... population, though it is often unaddressed. Forty-eight million Americans ... a hearing aid, mainly due to price. Hearing aids ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Audicus Will Help People Resolve to Hear Better in 2015 2
... /PRNewswire-FirstCall/ --,Genta Incorporated announced the presentation of ... its marketed product, Ganite(R) (gallium,nitrate injection), plus ... relapsed or refractory non-Hodgkin's,lymphoma (NHL). The data ... American Society of Clinical Oncology (ASCO) in ...
... in 35% of HER2-Positive Metastatic Breast,Cancer ... /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated presented data ... that alvespimycin, its second-generation Hsp90,inhibitor, demonstrated ... with trastuzumab (Herceptin(R)) in,patients with refractory ...
Cached Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 2Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 3Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 4Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 6
(Date:12/21/2014)... 2014 Parker & Sons, Inc. a ... plumbing and other similar home contractor services announces a ... to its expert contracting services. The company is considered ... been serving Arizona for well over 40 years. Parker ... best in quality customer service to the residents and ...
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at the ... its kind, the site has provided its faithful users with ... running. It uniquely combines the benefits of platforms like ... to the masses. Assuring the potent herb’s followers it’s ... public approval. , Shane Chattin, Owner of Cannabis ...
(Date:12/20/2014)... December 21, 2014 MissyDress, a distinguished ... all prom lovers. The business has drastically cut prices ... dresses to everyone until Jan. 30, 2015. Many of ... sweetheart dresses, V-neck dresses, lace dresses, and more. , ... not there every day. Whether A-line princess prom dresses ...
(Date:12/20/2014)... print component of Healthy Aging is distributed within today’s ... and an estimated readership of 420,000. The digital component ... and across a network of top news sites and ... campaign, click here . , The publication features ... The Social. Lainey Lui, Melissa Grelo, Traci Melchor, ...
(Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... guest speakers included a World Health Organization expert ... 27 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), ... conference in Toronto this week,entitled, "E. coli O157 ... veterinarians and representatives from the food industry: Beef,dairy, ...
... Nursing Students Educate Community in Hydration and Sanitation, Sand Bag ... ... Eighteen Sanford-Brown students assisted Missouri community residents who were ... bagging, the nursing students ensured that Clarksville families were educated on ...
... Insurance Plan Provides Affordable Medical Insurance, Making Urgent Care Available to ... ... Mesa, AZ (PRWEB) June 27, 2008 -- NextCare ( ... announced the implementation of a new affordable medical insurance plan, CareForToday. ...
... around the world will present their latest research on indicators of ... of identification, and strategies for early intervention. These experts have been ... and toddlers to escape the life altering consequences of autism spectrum ... ...
... SANTA ANA, Calif., June 26 Grubb & ... SouthCrest Medical Plaza, a,two- building medical office property ... Located at 1035 and 1045 Southcrest Drive, SouthCrest ... gross leaseable area,situated on approximately 9.7 acres of ...
... Gun-related homicide among young men rose sharply in the United ... rate remained flat, according to a study by researchers at ... and 2005, homicide involving firearms increased 31 percent among black ... men of the same age. The study is published in ...
Cached Medicine News:Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 2Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 3Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 4Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 5Health News:Sanford-Brown College Students Help in Missouri Flood Relief 2Health News:Urgent Care Provider NextCare Introduces CareForToday Medical Insurance Plan 2Health News:The Second International Conference on Signs of Autism in Infants: Changing Outcomes through Early Identification and Intervention, October 11 and 12, 2008. Save the Date! 2Health News:The Second International Conference on Signs of Autism in Infants: Changing Outcomes through Early Identification and Intervention, October 11 and 12, 2008. Save the Date! 3Health News:Grubb & Ellis Healthcare REIT Acquires SouthCrest Medical Plaza in Stockbridge, Ga. 2Health News:Grubb & Ellis Healthcare REIT Acquires SouthCrest Medical Plaza in Stockbridge, Ga. 3Health News:Researchers study hidden homicide trend 2
... Implant (KGTI) system offers the latest technology ... MPJ. The implant system is anatomically designed ... ,The KGTI is the most advanced reconstructive ... on the market today. The system consists ...
... Nerve Electrodes provide direct cranial nerve ... patented circumferential design provides sensitive contact ... stable real-time recordings. This unique approach ... the removal of acoustic neuromas, microvascular ...
... Ad-Techs Model CMU Cortical Mapping Unit ... of recording EEGs from exposed cortex during ... each electrode plate can be positioned independently ... clamp provides two alternative mounting locations and ...
An ambulatory recorder can help the patient be more comfortable and at ease as well as increasing an EEG laboratory's recording capacity....
Medicine Products: